Ability of Tumor Markers for Predicting Future Metastatic Disease in MEN-1 Patients with a Pancreatic Neuroendocrine Tumor

#666

Introduction: The diagnostic value of tumor markers in the follow-up of MEN-1 patients with a pancreatic neuroendocrine tumor (pNET) is unclear.

Aim(s): To assess the ability of chromogranin A (CgA), pancreatic polypeptide (PP) and glucagon at diagnosis of pNET and the course at long-term follow-up for predicting future metastatic disease in MEN-1 patients.

Materials and methods: A longitudinal study (1990 – 2010) using the Dutch national MEN-1 database, including 90% of the MEN-1 population in the Netherlands, was performed. pNET was diagnosed by pathology or by MRI, CT or EUS confirmed on further imaging. Reference standard for metastatic disease was pathology or imaging. Linear mixed models were applied with metastatic disease and somatostatin analogues (SSA) as possible effect modifiers.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: De Laat J, Pieterman C, Twisk J, Hermus A, Dekkers O,

Keywords: MEN-1, tumor marker, pNET, SSA,